Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells

• Stuart G. Turville

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

• John J. Santos

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

• Ines Frank

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

• Paul U. Cameron

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

• John Wilkinson

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

• Monica Miranda-Saksena

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

• Joanne Dable

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

• Hella Stössel

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

• Nikolaus Romani

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

• Michael Piatak

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

• Jeffrey D. Lifson

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

• Melissa Pope

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

• Anthony L. Cunningham

  From the Centre For Virus Research, Westmead Millennium Institute, Sydney, Australia; Center for Biomedical Research, Population Council, New York, NY; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; the Department of Dermatology and Venereology, University of Innsbruck, Austria; and the AIDS Vaccine Program, Science Applications International Corporation (SAIC)–Frederick, National Cancer Institute at Frederick, Frederick, MD.

抄録

HIV-1 subverts antigen processing in dendritic cells (DCs) resulting in viral uptake, infection, and transfer to T cells. Although DCs bound monomeric gp120 and HIV-1 similarly, virus rarely colocalized with endolysosomal markers, unlike gp120, suggesting HIV-1 alters endolysosomal trafficking. Virus within DC intracellular compartments rapidly moved to DC-CD4+ lymphocyte synapses when introduced to CD4+ lymphocyte cultures. Although viral harboring and transfer from nonlysosomal compartments was transient, given DC-associated virus protein, nucleic acids, and infectious HIV-1 transfer to CD4+, lymphocytes decayed within 24 hours. However a second long-term transfer phase was apparent in immature DCs after 48 hours as a zidovudine-sensitive rise in proviral DNA. Therefore, DCs transfer HIV-1 to CD4+ lymphocytes in 2 distinct phases. Immature and mature DCs first divert virus from the endolysosomal pathway to the DC–T-cell synapse. Secondly, the later transfer phase from immature DCs is through de novo HIV-1 production. Thus, the controversy of DCs being infected or not infected for the mechanics of viral transfer to CD4+ lymphocytes can be addressed as a function of time.

収録刊行物

• Blood

  Blood 103 (6), 2170-2179, 2004-03-15

  American Society of Hematology

キーワード

• Cell Biology
• Hematology
• Immunology
• Biochemistry

詳細情報

• CRID: 1363107369667852928
• NII論文ID: 30022497260
• DOI: 10.1182/blood-2003-09-3129
• ISSN: 15280020
• ISSN: 00064971
• Web Site: http://ashpublications.org/blood/article-pdf/103/6/2170/1696793/zh800604002170.pdf
• データソース種別:
  • Crossref
  • CiNii Articles